Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) Enterprise Value (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Enterprise Value for 6 consecutive years, with -$147.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 35.46% to -$147.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$147.3 million, a 35.46% increase, with the full-year FY2024 number at -$209.5 million, up 36.28% from a year prior.
  • Enterprise Value was -$147.3 million for Q3 2025 at Caribou Biosciences, up from -$183.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$129.5 million in Q2 2021 to a low of -$435.3 million in Q3 2021.
  • A 5-year average of -$270.2 million and a median of -$260.4 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 2255.87% in 2021, then skyrocketed 36.28% in 2024.
  • Caribou Biosciences' Enterprise Value stood at -$375.8 million in 2021, then surged by 34.1% to -$247.7 million in 2022, then tumbled by 32.77% to -$328.8 million in 2023, then surged by 36.28% to -$209.5 million in 2024, then grew by 29.72% to -$147.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Enterprise Value are -$147.3 million (Q3 2025), -$183.9 million (Q2 2025), and -$208.5 million (Q1 2025).